Cabazitaxel: a new drug for metastatic prostate cancer
- PMID: 21151153
- PMCID: PMC3592929
- DOI: 10.1038/aja.2010.161
Cabazitaxel: a new drug for metastatic prostate cancer
References
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49. - PubMed
-
- Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jr, Jones JA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
-
- Sartor A, Oudard S, Ozguroglu M, Hansen S, Machiels J, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract]. Proceedings of the ASCO Genitourinary Cancers Symposium; 5–7 March San Francisco, CA, USAASCO: Alexandria, VA, USA, 2010, No. 9.2010
-
- Brooks TA, Minderman H, O'Loughlin KL, Pera P, Ojima I, et al. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Mol Cancer Ther. 2003;2:1195–205. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
